Lexi Ding
- Ophthalmology top 2%
- Retinal Diseases and Treatments 7
- Glaucoma and retinal disorders 2
- Clinical Biochemistry top 5%
- Physiology top 10%
- Adipose Tissue and Metabolism 2
- Neurology top 10%
-
- Peroxisome Proliferator-Activated Receptors 7
- Retinal Development and Disorders 2
-
- Endoplasmic Reticulum Stress and Disease 2
-
- Eicosanoids and Hypertension Pharmacology 2
-
- MicroRNA in disease regulation 2
- Journals
- Frontiers in Endocrinology (5 papers)Investigative Ophthalmology & Visual Science (4 papers)Diabetes (2 papers)
- Partner nations
- ChinaUnited StatesAustralia
In The Last Decade
Lexi Ding
24 papers receiving 735 citations
Peers
Comparison fields: 5 of 73
- Ophthalmology 247
- Clinical Biochemistry 77
- Physiology 45
- Neurology 65
- Molecular Biology 422
Countries citing papers authored by Lexi Ding
This map shows the geographic impact of Lexi Ding's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lexi Ding with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lexi Ding more than expected).
Fields of papers citing papers by Lexi Ding
This network shows the impact of papers produced by Lexi Ding. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lexi Ding. The network helps show where Lexi Ding may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Lexi Ding, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2022 | 21 | |
| 3 | 2022 | 8 | |
| 4 | 2022 | 2 | |
| 5 | 2022 | 5 | |
| 6 | 2022 | 33 | |
| 7 | 2022 | 38 | |
| 8 | 2021 | 8 | |
| 9 | 2021 | 2 | |
| 10 | 2021 | 24 | |
| 11 | 2020 | 18 | |
| 12 | 2020 | 23 | |
| 13 | 2019 | 50 | |
| 14 | 2019 | 35 | |
| 15 | 2018 | 3 | |
| 16 | 2017 | 12 | |
| 17 | 2016 | 61 | |
| 18 | 2014 | 74 | |
| 19 | 2014 | 63 | |
| 20 | THE PATHOGENIC ROLE OF DOWN-REGULATION OF PPAR-ΑLPHA EXPRESSION IN DIABETIC RETINOPATHY | 2013 | 1 |
About Lexi Ding
Lexi Ding is a scholar working on Ophthalmology, Neurology and Clinical Biochemistry, having authored 25 papers that have together received 748 indexed citations. Recurring topics across this work include Retinal Diseases and Treatments (7 papers), Peroxisome Proliferator-Activated Receptors (7 papers), Endoplasmic Reticulum Stress and Disease (2 papers), Eicosanoids and Hypertension Pharmacology (2 papers), MicroRNA in disease regulation (2 papers), Adipose Tissue and Metabolism (2 papers), Glaucoma and retinal disorders (2 papers) and Retinal Development and Disorders (2 papers). The work is most often cited by research in Ophthalmology (247 citations), Clinical Biochemistry (77 citations) and Physiology (45 citations). Lexi Ding has collaborated with scholars based in China, United States and Australia. Frequent co-authors include Jian‐xing Ma, Rui Cheng, Yusuke Takahashi, Yang Hu, Xuemin He, Ying Chen, Siqi Xiong, Xiaobo Xia, Kyungwon Lee and Elizabeth Moran. Their work appears in journals such as Frontiers in Endocrinology, Investigative Ophthalmology & Visual Science, Diabetes, Biomedicine & Pharmacotherapy and Molecular Therapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.